Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Candel Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Investor Contact"
06/29/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact"
05/19/2023 8-K Investor presentation
Docs: "106 0 0 NA NA 2",
"Investor Contact"
05/11/2023 8-K Quarterly results
Docs: "Investor Contact"
05/09/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statements and Exhibits  Interactive ...
04/17/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
02/22/2023 8-K Regulation FD Disclosure  Interactive Data
12/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
12/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "R&D Day Corporate Presentation",
"R&D Day Corporate Presentation"
11/29/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Candel Therapeutics to Host Virtual R&D Day on December 6, 2022 • New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer. • Recent clinical data for CAN-3110 and CAN-2409 in high-grade glioma to be presented. • Scientific rationale for the recently announced collaboration with the University of Pennsylvania using Candel’s enLIGHTEN™ discovery platform to be discussed. • Premier experts and thought leaders in immunology and oncology to share perspectives on broad, potential, therapeutic combination synergies and growing opportunity for Candel’s novel viral immunotherapies. NEEDHAM, Mass., November 29, 2022 --"
11/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting • CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissue • No dose-limiting toxicities observed in 41 patients with recurrent high-grade glioma • Median overall survival was 11.6 months after a single injection of CAN-3110 in patients with rHGG; one patient achieved a complete response lasting more than one year • CAN-3110 observed to activate lymphocyte-depleted tumor microenvironment in rHGG, with changes in T cell receptor repertoire associated with survival NEEDHAM, Mass., November 18, 2022..."
10/14/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/07/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
Docs: "Investor Contact"
08/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Candel Therapeutics Appoints Three New Members to its Board of Directors"
06/06/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/29/2022 8-K Quarterly results
Docs: "Investor Contact"
03/01/2022 8-K Quarterly results
02/09/2022 8-K Quarterly results
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/12/2021 8-K Quarterly results
Docs: "Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Nov. 12, 2021 — Candel Therapeutics, Inc."
09/08/2021 8-K Quarterly results
08/17/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters' Option August 17, 2021 NEEDHAM, Mass., August 17, 2021 - Candel Therapeutics, Inc. , a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the closing of the issuance of an additional 887,994 shares of its common stock at a public offering price of $8.00 per share. The shares were issued pursuant to a partial exercise of the underwriters' option to purchase additional shares of common stock in connection with Candel's previously announced initial public offering of 9,000,000 shares of its common stock. The gross proceeds from the exercise of the option to purchase additional shares were approximately $7.1 million, brin..."
07/29/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy